Asper Biotech

Asper Biotech has updated its Ashkenazi Jewish Diseases Test to include mutations in the BRCA1, BRCA2, and LCA5 genes that are common in the Ashkenazi Jewish population. Asper's test now detects up to 112 variants in 27 genes.

Asper Biotech recently introduced a number of new test panels targeted to mitochondrial diseases.

Asper Biotech recently launched a new carrier test to detect the most common mutations associated with autosomal recessive disorders that are overrepresented in the Hutterite population.

From its office in Tartu, Estonia, Asper Biotech continues to introduce new microarray-based tests related to reproductive health, oncology, and opthamalogy.

Asper Biotech recently launched a test for Leber hereditary optic neuropathy, or LHON, a disease characterized by optic nerve dysfunction that leads to painless, subacute loss of central vision.

Asper Biotech recently launched several new reprogenetic tests. The Tartu, Estonia-based firm uses arrayed primer extension to test fetal cells for specific genetic abnormalities.

By Justin Petrone
This story was originally posted Sept. 10
Asper Biotech has introduced array-based prenatal testing for fetuses with increased nuchal translucency but normal karyotype.

New Product Watch

Premium

Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.

New Product Watch

Premium

Asper Biotech's Sensorineural Hearing Loss Test, Fujifilm's DMP-5005 Materials Printer, BioForce Nanosciences' ProCleaner Plus

New Product Watch

Premium

Anagnostics' Hyborg System, Asper Biotech's Congenital Stationary Night Blindness Genetic Test

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.